GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
3.430 USD   +0.88%
08/04GRITSTONE BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
08/04GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/04Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $5.5M
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
2.49(c) 2.53(c) 2.8(c) 3.4(c) 3.43(c) Last
504 759 295 550 507 128 1 719 071 1 135 249 Volume
-1.97% +1.61% +10.67% +21.43% +0.88% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 19,5 M - -
Net income 2022 -123 M - -
Net cash position 2022 23,0 M - -
P/E ratio 2022 -2,18x
Yield 2022 -
Sales 2023 13,9 M - -
Net income 2023 -138 M - -
Net Debt 2023 4,59 M - -
P/E ratio 2023 -2,16x
Yield 2023 -
Capitalization 250 M 250 M -
EV / Sales 2022 11,6x
EV / Sales 2023 18,3x
Nbr of Employees 201
Free-Float 97,0%
More Financials
Company
Gritstone bio, Inc. is a biotechnology company. The Company discover, develop, manufacture and deliver next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared... 
Sector
Pharmaceuticals
Calendar
11/15Earnings Release
More about the company
Ratings of Gritstone bio, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GRITSTONE BIO, INC.
08/04GRITSTONE BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update..
PU
08/04GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
08/04Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $5.5M
MT
08/04TRANSCRIPT : Gritstone bio, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update
AQ
08/04Gritstone bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
07/26Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
07/22GRITSTONE BIO, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
07/21Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update ..
AQ
07/21Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and S..
AQ
07/21Gritstone Bio, Inc. Enters into an $80 Million Credit Facility with Hercules Capital, I..
CI
07/05Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell Small Cap Comp Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 3000E Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 2500 Value Index
CI
More news
News in other languages on GRITSTONE BIO, INC.
08/04Earnings Flash (GRTS) GRITSTONE BIO annonce un revenu de 5,5 millions de dollars pour l..
08/04Gritstone bio, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clo..
06/10Gritstone annonce les résultats de l'étude préclinique de son vaccin auto-amplificateur..
05/31Gritstone Bio, Inc. Annonce des résultats actualisés de survie globale chez des patient..
05/05Earnings Flash (GRTS) GRITSTONE BIO affiche un revenu de 7,2 millions de dollars pour l..
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,43 $
Average target price 16,00 $
Spread / Average Target 366%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
Erin E. Jones Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-73.33%250
CSL LIMITED2.07%98 543
SAMSUNG BIOLOGICS CO.,LTD.-0.89%48 860
WUXI BIOLOGICS (CAYMAN) INC.-19.88%40 273
BIOGEN INC.-9.05%31 664
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-19.97%23 596